Staunton, Jocelyn

Design of Development Candidate eFT226, a First in Class Inhibitor of Eukaryotic Initiation Factor 4A RNA Helicase

Ernst, J. T., Thompson, P. A., Nilewski, C., Sprengeler, P. A., Sperry, S., Packard, G., Michels, T., Xiang, A., Tran, C., Wegerski, C. J., et al. (2020) · Journal of Medicinal Chemistry

RNA and protein synthesis mechanismsPI3K/AKT/mTOR signaling in cancer

Cited by 150

Targeting Oncogene mRNA Translation in B-Cell Malignancies with eFT226, a Potent and Selective Inhibitor of eIF4A

Thompson, P. A., Eam, B., Young, N. P., Fish, S., Chen, J., Barrera, M., Howard, H., Sung, E., Parra, A., Staunton, J., et al. (2021) · Molecular Cancer Therapeutics

PI3K/AKT/mTOR signaling in cancerRNA and protein synthesis mechanisms

Cited by 50

Abstract 5948: FMC-376 a dual inhibitor of ON and OFF states of KRASG12C is broadly active in PDX models of resistance

Wang, Y., Neve, R. M., Staunton, J., & Webster, K. R. (2024) · Cancer Research

Protein Kinase Regulation and GTPase SignalingLung Cancer Treatments and Mutations

Cited by 7